Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents

Journal of Infection and Chemotherapy

Volumn 21, Issue 5, 2015, Pages 319-329

  Asín Prieto, Eduardo ^a   Rodríguez Gascón, Alicia ^a   Isla, Arantxazu ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Breakpoints; Monte Carlo simulation; Pharmacodynamics; Pharmacokinetics; PK PD analysis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; COLISTIN; DAPTOMYCIN; LINEZOLID; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TEICOPLANIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; CRITICALLY ILL PATIENT; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; GERIATRIC PATIENT; HUMAN; INFECTION PREVENTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OBESITY; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; POSTOPERATIVE INFECTION; REVIEW; SURGICAL INFECTION; SURGICAL WOUND; AGE; BACTERIAL INFECTIONS; COMPLICATION; CRITICAL ILLNESS; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

AGE FACTORS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; OBESITY;

EID: 84933046174     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2015.02.001     Document Type: Review

References (112)

1. World Health Organization Antimicrobial resistance. Global report on surveillance 2014, Available at:, [accessed: Oct 2014]. http://www.who.int/drugresistance/documents/AMR_report_Web_slide_set.pdf.
2. World Health Organization WHO's first global report on antibiotic resistance reveals serious, worldwide threat to public health 2014, Available at:, [accessed: Oct 2014]. http://www.who.int/mediacentre/news/releases/2014/amr-report/en/.
3. Davies J. Where have all the antibiotics Gone?. Can J Infect Dis Med Microbiol 2006, 17:287-290.
4. Braine T. Race against time to develop new antibiotics. Bull World Health Organ 2011, 89:88-89.
5. Wright G. Antibiotics: a New Hope. Chem Biol 2012, 19:3-10.
6. Fowler T., Walker D., Davies S.C. The risk/benefit of predicting a post-antibiotic era: is the alarm working?. Ann N Y Acad Sci 2014, 1323:1-10.
7. Silver L.L. Challenges of antibacterial discovery. Clin Microbiol Rev 2011, 24:71-109.
8. Mishra R.P., Oviedo-Orta E., Prachi P., Rappuoli R., Bagnoli F. Vaccines and antibiotic resistance. Curr Opin Microbiol 2012, 15:596-602.
9. Torrecilla J., Rodriguez-Gascon A., Solinis M.A., del Pozo-Rodriguez A. Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives. Biomed Res Int 2014, 2014:161794. 10.1155/2014/161794.
10. Matsuzaki S., Rashel M., Uchiyama J., Sakurai S., Ujihara T., Kuroda M., et al. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. JInfect Chemother 2005, 11:211-219.
11. Henry B.D., Neill D.R., Becker K.A., Gore S., Bricio-Moreno L., Ziobro R., et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotech 2014, 10.1038/nbt.3037.
12. Olofsson S.K., Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis 2007, 45:S129-S136.
13. Martinez M.N., Papich M.G., Drusano G.L. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 2012, 56:2795-2805.
14. Mouton J.W., Dudley M.N., Cars O., Derendorf H., Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. JAntimicrob Chemother 2005, 55:601-607.
15. Andes D., Craig W.A. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002, 19:261-268.
16. Sy S.K.B., Derendorf H. Pharmacometrics in bacterial infections 2014, 229-258. Springer, New York. S. Schmidt, H. Derendorf (Eds.).
17. Michael J., Barth A., Kloft C., Derendorf H. Pharmacodynamic invitro models to determine the effect of antibiotics 2014, 81-112. Springer, New York. A.A. Vinks, H. Derendorf, J.W. Mouton (Eds.).
18. Schmidt S., Barbour A., Sahre M., Rand K.H., Derendorf H. PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol 2008, 8:549-556.
19. Velkov T., Bergen P.J., Lora-Tamayo J., Landersdorfer C.B., Li J. PK/PD models in antibacterial development. Curr Opin Microbiol 2013, 16:573-579.
20. Roberts J.A., Kirkpatrick C.M.J., Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. JAntimicrob Chemother 2011, 66:227-231.
21. Asin E., Isla A., Canut A., Rodriguez Gascon A. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria. Int J Antimicrob Agents 2012, 40:313-322.
22. Canut A., Isla A., Betriu C., Gascón A.R. Pharmacokinetic-Pharmacodynamic evaluation of daptomycin, tigecycline and linezolid versus vancomycin for the treatment of MRSA infections in four Western European Countries. Eur L Clin Microbiol Infect Dis 2012, 31:2227-2235.
23. Goff D.A., Nicolau D.P. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents. Clin Ther 2013, 35:766-771.
24. Turnidge J., Paterson D.L. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 2007, 20:391-408.
25. Frei C.R., Wiederhold N.P., Burgess D.S. Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. JAntimicrob Chemother 2008, 61:621-628.
26. Mouton J.W., Brown D.F.J., Apfalter P., Cantón R., Giske C.G., Ivanova M., et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 2012, 18:E37-E45.
27. DeRyke C.A., Kuti J.L., Nicolau D.P. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 2007, 58:337-344.
28. Ikawa K., Morikawa N., Ikeda K., Ohge H., Sueda T. Development of breakpoints of cephems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in the peritoneal fluid of patients. JInfect Chemother 2008, 14:141-146.
29. Ikawa K., Morikawa N., Ikeda K., Ohge H., Sueda T. Development of breakpoints of carbapenems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluid. JInfect Chemother 2008, 14:330-332.
30. European Committee on Antimicrobial Susceptibility Testing EUCAST procedure for harmonising and defining breakpoints 2013, Available at:, [accessed Oct 2014]. http://www.srga.org/Eucastwt/bpsetting.htm.
31. Roberts J.A., Abdul-Aziz M.H., Lipman J., Mouton J.W., Vinks A.A., Felton T.W., et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014, 14:498-509.
32. Blot S.I., Pea F., Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient - concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 2014, 10.1016/j.addr.2014.07.006.
33. Ulldemolins M., Roberts J.A., Rello J., Paterson D.L., Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011, 50:99-110.
34. Udy A., Roberts J., Lipman J. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 2013, 39:2070-2082.
35. Baddour L.M., Yu V.L., Klugman K.P., Feldman C., Ortqvist A., Rello J., et al. Combination antibiotic therapy lowers mortality among severely ill patients with Pneumococcal Bacteremia. Am J Respir Crit Care Med 2014, 170:440-444.
36. Ikawa K., Morikawa N., Ikeda K., Suyama H. Pharmacokinetic modeling and dosage adaptation of biapenem in Japanese patients during continuous venovenous hemodiafiltration. JInfect Chemother 2008, 14:35-39.
37. Carlier M., Noë M., Roberts J.A., Stove V., Verstraete A.G., Lipman J., et al. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. JAntimicrob Chemother 2014, 69:2797-2803.
38. Carlier M., Carrette S., Roberts J.A., Stove V., Verstraete A., Hoste E., et al. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?. Crit Care 2013, 17:R84.
39. Roberts J.A., Kirkpatrick C.M., Roberts M.S., Dalley A.J., Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010, 35:156-163.
40. Roberts J.A., Udy A.A., Bulitta J.B., Stuart J., Jarrett P., Starr T., et al. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. JAntimicrob Chemother 2014, 69:2508-2516.
41. Gomez D.S., Sanches-Giraud C., Silva C., Oliveira V., AMRR da S., Gemperli R., et al. Imipenem in burn patients: pharmacokinetic profile and PK/PD target attainment. JAntibiot 2014, 10.1038/ja.2014.121.
42. Salem A.H., Zhanel G.G., Ibrahim S.A., Noreddin A.M. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus. Clin Exp Pharmacol Physiol 2014, 41:437-443.
43. Samtani M.N., Flamm R., Kaniga K., Nandy P. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients. Antimicrob Agents Chemother 2010, 54:2360-2364.
44. Garonzik S.M., Li J., Thamlikitkul V., Paterson D.L., Shoham S., Jacob J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011, 55:3284-3294.
45. Ikawa K., Morikawa N., Suyama H., Ikeda K., Yamanoue T. Pharmacokinetics and pharmacodynamics of once-daily arbekacin during continuous venovenous hemodiafiltration in critically ill patients. JInfect Chemother 2009, 15:420-423.
46. Blot S., Koulenti D., Akova M., Bassetti M., De Waele J.J., Dimopoulos G., et al. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Crit Care 2014, 18:R99.
47. Zhang L., Li L., Shi W., Liu S., Liang X., Ye Z., et al. Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration. Int J Antimicrob Agents 2013, 42:244-249.
48. Spooner A.M., Deegan C., D'Arcy D.M., Gowing C.M., Donnelly M.B., Corrigan O.I. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. BMC Clin Pharmacol 2011, 11:11. 10.1186/1472-6904-11-11.
49. Chant C., Leung A., Friedrich J.O. Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis. Crit Care 2013, 17:R279.
50. Yusuf E., Spapen H., Piérard D. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review. JCrit Care 2014, 29:1089-1095.
51. Sakka S.G., Glauner A.K., Bulitta J.B., Kinzig-Schippers M., Pfister W., Drusano G.L., et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007, 51:3304-3310.
52. Smyth A., Tan K.H., Hyman-Taylor P., Mulheran M., Lewis S., Stableforth D., et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005, 365:573-578.
53. Nicolau D.P., Freeman C.D., Belliveau P.P., Nightingale C.H., Ross J.W., Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995, 39:650-655.
54. Deguchi T., Seike K., Yasuda M., Matsumoto T. Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa. JInfect Chemother 2011, 17:726-730.
55. MacVane S.H., Kuti J.L., Nicolau D.P. Prolonging beta-lactam infusion: a review of the rationale and evidence, and guidance for implementation. Int J Antimicrob Agents 2014, 43:105-113.
56. Roberts D.M., Roberts J.A., Roberts M.S., Liu X., Nair P., Cole L., et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study*. Crit Care Med 2012, 40:1523-1528.
57. Isla A., Rodriguez-Gascon A., Troconiz I.F., Bueno L., Solinis M.A., Maynar J., et al. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet 2008, 47:173-180.
58. Asin-Prieto E., Rodriguez-Gascon A., Troconiz I.F., Soraluce A., Maynar J., Sanchez-Izquierdo J.A., et al. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. JAntimicrob Chemother 2014, 69:180-189.
59. Ulldemolins M, Vaquer S, Llauradó-Serra M, Pontes C, Calvo G, Soy D, etal. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy. 201406/23;18:1-16.
60. Tambyah P.A., Hara G.L., Daikos G.L., Falagas M.E., Mazzei T., Mouton J.W., et al. Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012. JGlob Antimicrob Resist 2013, 1:117-122.
61. Pea F., Viale P., Cojutti P., Furlanut M. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob Agents Chemother 2012, 56:6343-6348.
62. Yamamoto T., Yasuno N., Katada S., Hisaka A., Hanafusa N., Noiri E., et al. Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration. Antimicrob Agents Chemother 2011, 55:5804-5812.
63. Pea F., Furlanut M., Negri C., Pavan F., Crapis M., Cristini F., et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2009, 53:1863-1867.
64. Liu P., Müller M., Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 2002, 19:285-290.
65. Deitchman A.N., Derendorf H. Measuring drug distribution in the critically ill patient. Adv Drug Deliv Rev 2014, 10.1016/j.addr.2014.08.014.
66. Brunner M., Derendorf H., Müller M. Microdialysis for invivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr Opin Pharmacol 2005, 5:495-499.
67. Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses?. Curr Opin Pharmacol 2007, 7:498-504.
68. Ramsey B.W. Management of pulmonary disease in patients with cystic fibrosis. NEngl J Med 1996, 335:179-188.
69. Notkina N., Dahyot-Fizelier C., Gupta A.K. Invivo microdialysis in pharmacological studies of antibacterial agents in the brain. Brit J Anaesth 2012, 109:155-160.
70. Poeppl W., Zeitlinger M., Donath O., Wurm G., Müller M., Botha F., et al. Penetration of doripenem in human brain: an observational microdialysis study in patients with acute brain injury. Int J Antimicrob Agents 2012, 39:343-345.
71. Ikawa K., Nakashima A., Morikawa N., Ikeda K., Murakami Y., Ohge H., et al. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment. Antimicrob Agents Chemother 2011, 55:5609-5615.
72. Goncalves-Pereira J., Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care 2011, 15:R206.
73. Longo C., Bartlett G., MacGibbon B., Mayo N., Rosenberg E., Nadeau L., et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf 2013, 22:970-976.
74. Han P.Y., Duffull S.B., Kirkpatrick C.M.J., Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007, 82:505-508.
75. Cheatham S.C., Fleming M.R., Healy D.P., Chung E.K., Shea K.M., Humphrey M.L., et al. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. JClin Pharmacol 2014, 54:324-330.
76. Chen M., Nafziger A.N., Drusano G.L., Ma L., Bertino J.S. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 2006, 50:1222-1227.
77. Cheatham S.C., Fleming M.R., Healy D.P., Chung C.E.K., Shea K.M., Humphrey M.L., et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents 2013, 41:52-56.
78. Hollenstein U.M., Brunner M., Schmid R., Müller M. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obes 2001, 25:354-358.
79. Mangoni A.A., Jackson S.H. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004, 57:6-14.
80. Vincent J.L., Sakr Y., Sprung C.L., Ranieri V.M., Reinhart K., Gerlach H., et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353.
81. Leroy B., Uhart M., Maire P., Bourguignon L. Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. JAntimicrob Chemother 2012, 67:2207-2212.
82. Abe S., Chiba K., Cirincione B., Grasela T.H., Ito K., Suwa T. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. JClin Pharmacol 2009, 49:1071-1078.
83. Mahmood I. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin Pharmacokinet 2014, 53:327-346.
84. Anderson B.J., Holford N.H. Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child 2013, 98:737-744.
85. Sy S.K., Asin-Prieto E., Derendorf H., Samara E. Predicting pediatric age-matched weight and body mass index. AAPS J 2014, 16:1372-1379.
86. Downes K.J., Hahn A., Wiles J., Courter J.D., Vinks A.A. Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics. Int J Antimicrob Agents 2014, 43:223-230.
87. Ikawa K., Morikawa N., Ikeda K., Miki M., Kobayashi M. Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients. JInfect Chemother 2010, 16:139-143.
88. Thingvoll E.S., Guillet R., Caserta M., DiCenzo R. Observational trial of a 48-hour gentamicin dosing regimen derived from monte carlo simulations in infants Born at less than 28 Weeks' Gestation. JPediatr 2008, 153:530-534.
89. Beobide I., Canut A., Gascon A.R., Isla A., Garcia-Rey C., De La Maza I., et al. Evaluation of antimicrobial treatments in children with acute otitis media in Spain: a pharmacokinetic-pharmacodynamic (PK/PD) approach. JChemother 2005, 17:628-635.
90. Isla A., Troconiz I.F., Canut A., Labora A., Martin-Herrero J.E., Pedraz J.L., et al. Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain. Enferm Infecc Microbiol Clin 2011, 29:167-173.
91. Muller A.E., Mouton J.W. Continuous infusion of beta-lactam antibiotics. Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics New York 2014, 223-255. Springer, Heidelberg Dordrecht London. A.A. Vinks, H. Derendorf, J.W. Mouton (Eds.).
92. Buijk S.L.C.E., Gyssens I.C., Mouton J.W., Van Vliet A., Verbrugh H.A., Bruining H.A. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. JAntimicrob Chemother 2002, 49:121-128.
93. Kosaka T., Hosokawa K., Shime N., Taniguchi F., Kokufu T., Hashimoto S., et al. Effects of renal function on the pharmacokinetics and pharmacodynamics of prophylactic cefazolin in cardiothoracic surgery. Eur J Clin Microbiol Infect Dis 2012, 31:193-199.
94. Yasuda M., Nakane K., Yamada Y., Matsumoto M., Sho T., Matsumoto M., et al. Clinical effectiveness and safety of tazobactam/piperacillin 4.5 g for the prevention of febrile infectious complication after prostate biopsy. JInfect Chemother 2014, 20:631-634.
95. Pevzner L., Swank M., Krepel C., Wing D.A., Chan K., Edmiston C.E. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol 2011, 117:877-882.
96. Edmiston C.E., Krepel C., Kelly H., Larson J., Andris D., Hennen C., et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels?. Surgery 2004, 136:738-747.
97. Isla A., Trocóniz I., de Tejada I., Vázquez S., Canut A., López J., et al. Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery. Eur J Clin Pharmacol 2012, 68:735-745.
98. Asin-Prieto E., Soraluce A., Troconiz I.F., Campo E., Saenz de Ugarte J., Rodriguez-Gascon A., et al. Population pharmacokinetic models for cefuroxime and metronidazole used in combination as prophylactic agents in colorectal surgery: model based evaluation of standard dosing regimens. Int J Antimicrob Agents 2015, 10.1016/j.ijantimicag.2015.01.008.
99. Deziel M.R., Heine H., Louie A., Kao M., Byrne W.R., Basset J., et al. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob Agents Chemother 2005, 49:5099-5106.
100. Drusano G.L., Okusanya O.O., Okusanya A., Van Scoy B., Brown D.L., Kulawy R., et al. Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?. Antimicrob Agents Chemother 2008, 52:3973-3979.
101. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004, 2:289-300.
102. Kashuba A.D., Nafziger A.N., Drusano G.L., Bertino J.S. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999, 43:623-629.
103. Aminimanizani A., Beringer P., Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 2001, 40:169-187.
104. Schentag J.J. Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients. Am J Health Syst Pharm 1999, 56:S21-S24.
105. Burgess D.S., Frei C.R., Lewis Ii J.S., Fiebelkorn K.R., Jorgensen J.H. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis. Clin Microbiol Infect 2007, 13:33-39.
106. Moise-Broder P.A., Forrest A., Birmingham M.C., Schentag J.J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004, 43:925-942.
107. Greenberg R.N., Benes C.A. Time-kill studies with oxacillin, vancomycin, and teicoplanin versus Staphylococcus aureus. JInfect Dis 1990, 161:1036-1037.
108. Brink A.J., Richards G.A., Cummins R.R., Lambson J. Gauteng Understanding Teicoplanin Serum levels (GUTS) study group. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Int J Antimicrob Agents 2008, 32:455-458.
109. Safdar N., Andes D., Craig W.A. Invivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004, 48:63-68.
110. Meagher A.K., Passarell J.A., Cirincione B.B., Van Wart S.A., Liolios K., Babinchak T., et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007, 51:1939-1945.
111. Matsumoto K., Shigemi A., Takeshita A., Watanabe E., Yokoyama Y., Ikawa K., et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents 2014, 44:242-247.
112. Bergen P.J., Li J., Nation R.L. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol 2011, 11:464-469.